Exelixis is trading with a PEG ratio of 0.34, based on Sep 2, 2026 data. Dividing the 17.79 PE ratio by the 53.0% earnings growth rate yields this valuation metric. Relative to the 0.31 average from the previous four quarters, the PEG ratio has grown by 11%.
Historically, Exelixis shows a PEG ratio averaging 0.8 across the past ten years. At 0.34, today's PE to growth ratio sits 58% below its historical average. The ten years high occurred in the Mar 2017 quarter at 6.99, reflecting maximum valuation relative to growth. The minimum was hit in the Mar 2018 quarter at 0.01, indicating optimal value relative to growth during that period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.25 | 15.22 | 60% |
| 2024 | 0.1 | 18.5 | 176.9% |
| 2023 | 2.64 | 36.91 | 14% |
| 2022 | N/A | 28.14 | -21.9% |
| 2021 | 0.24 | 25.04 | 102.8% |
| 2020 | N/A | 55.75 | -66% |
| 2019 | N/A | 16.62 | -54.3% |
| 2018 | 0.02 | 8.48 | 346.2% |
| 2017 | 0.2 | 58.46 | 285.7% |
| 2016 | N/A | N/A | 63.6% |
| 2015 | N/A | N/A | 42.5% |
| 2014 | N/A | N/A | -0.8% |
| 2013 | N/A | N/A | -44.6% |
| 2012 | N/A | N/A | -253.3% |
| 2011 | 0.05 | 7.89 | 170.6% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 0.31 | 16.54 | 53% |
| Mar 2026 | 0.36 | 13.75 | 38.7% |
| Dec 2025 | 0.25 | 15.22 | 60% |
| Sep 2025 | 0.3 | 16.79 | 55.7% |
| Jun 2025 | 0.24 | 20.5 | 83.8% |
| Mar 2025 | 0.07 | 16.41 | 251.6% |
| Dec 2024 | 0.1 | 18.5 | 176.9% |
| Sep 2024 | 0.04 | 16.42 | 464.3% |
| Jun 2024 | 0.15 | 19.21 | 129.4% |
| Mar 2024 | 1.11 | 37.08 | 33.3% |
| Dec 2023 | 2.64 | 36.91 | 14% |
| Sep 2023 | N/A | 78.04 | -70.8% |
| Jun 2023 | N/A | 37.47 | -40% |
| Mar 2023 | N/A | 40.44 | -48.9% |
| Dec 2022 | N/A | 28.14 | -21.9% |
Measured against past performance, EXEL's PEG ratio is below the 3, 5 and 10-year averages.
With a PEG of 0.34, EXEL is above the industry average but below the Healthcare sector average. Compared to its Healthcare sector average of 0.57, Exelixis's PEG is 40% lower.
Compared to its peers, EXEL has a PEG ratio under stock AMGN, while above BMY's.
According to Sep 2, 2026 data, EXEL's PEG ratio sits at 0.34.
Over the last 3 years, EXEL's PEG ratio has settled near 0.51.
Over the last 5 years, EXEL's PEG ratio has settled near 0.8.
EXEL's PEG ratio peaked at 6.99 during the Mar 2017 quarter - the highest in ten years.
Compared to the 10-year average, EXEL's PEG ratio is 58% lower.
Strong earnings growth relative to valuation produces EXEL's low PEG ratio of 0.34.
PEG equals PE divided by EPS growth (YoY TTM). As of Sep 2, 2026, Exelixis has a P/E ratio of 17.79. Earnings grew at 53.0% over the TTM period ending Jun 2026. Applying the formula, this produces a price to earnings growth ratio of 0.34. PEG RATIO(0.34) = PE RATIO(17.79) / EPS GROWTH(53.0%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.